Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Why do breast cancer patients in northern france wait too long for treatment?

NCT ID NCT07475325

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why women in the Hauts-de-France region of France may wait longer to start breast cancer treatment, even though they get cancer at similar rates as elsewhere. Researchers will track 500 women from their first symptom to their first treatment, breaking down delays into steps like getting a mammogram or biopsy. The goal is to find out what personal or social factors cause these delays, so care can be improved.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult women with recently diagnosed invasive breast carcinoma, receiving care in a participating Hauts-de-France center.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female, age ≥ 18 years. * Confirmed invasive breast carcinoma. * Diagnosis in 2024 (and/or \< 12 months at inclusion depending on center organization). * Affiliated with the French social security system. * Resident of Hauts-de-France since diagnosis. * Information provided and non-opposition documented (MR-003). Exclusion Criteria: * Male breast cancer. * Other histologies (phyllodes tumor, sarcoma, lymphoma). * Pure ductal carcinoma in situ (in situ only). * Personal history of breast cancer (including in situ). * Non-French-speaking. * Person deprived of liberty.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Invasive breast carcinoma

Contacts and locations

Locations

  • CH Beauvais

    Beauvais, 60000, France

  • CH Bethune

    Béthune, 62408, France

  • CH Boulogne

    Boulogne, 62321, France

  • CH Calais

    Calais, 62107, France

  • CH Chauny

    Chauny, 02300, France

  • CH Compiègne

    Compiègne, 60321, France

  • CH Dunkerque

    Dunkirk, 59385, France

  • CH Lens

    Lens, 62300, France

  • CH Roubaix

    Roubaix, 59100, France

  • CH Soissons

    Soissons, 02200, France

  • CH St Quentin

    Saint-Quentin, 02321, France

  • CH Tourcoing

    Tourcoing, 59208, France

  • CH Valenciennes

    Valenciennes, 59322, France

  • CHU Amiens

    Amiens, 80054, France

  • CHU Lille

    Lille, 59037, France

  • Centre Gray

    Maubeuge, 59600, France

  • Centre Leonard de Vinci

    Dechy, 59187, France

  • Centre Marie Curie

    Arras, 62000, France

  • Centre Oscar Lambret

    Lille, 59000, France

  • Centre Pierre Curie

    Beuvry, 62321, France

  • Centre de Radiothérapie de Compiègne

    Compiègne, 60200, France

  • Centre de Radiothérapie de Creil

    Creil, 60100, France

  • Clinique Ste Isabelle

    Abbeville, 80100, France

  • Clinique Victor Pauchet

    Amiens, 80090, France

  • Clinique de Flandre

    Coudekerque-Branche, 59210, France

  • Clinique de la Victoire

    Tourcoing, 59200, France

  • Clinique des dentellières

    Valenciennes, 59300, France

  • Hôpital St Vincent

    Lille, 59000, France

  • Hôpital privé Le Bois

    Lille, 59000, France

  • Hôpital privé Les Bonnettes

    Arras, 62000, France

  • Institut Andrée Dutreix

    Dunkirk, 59240, France

  • Polyclinique St Côme

    Compiègne, 60200, France

  • Polyclinique d'Hénin-Beaumont

    Hénin-Beaumont, 62254, France

  • Polyclinique de la Clarence

    Divion, 62460, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.